Eisai’s Cancer Strategy Bears Early IO Combo Fruit

Interim data from a Phase Ib/II of a combination of Eisai’s halichondrin Halaven with Merck & Co’s immuno-oncology product Keytruda suggest it could represent a novel treatment regimen in patients with metastatic triple negative breast cancer, in an early vindication for the Japanese company’s strategy of expanding its oncology franchise.